T1	Participants 46 76	chronic schizophrenic patients
T2	Participants 248 284	40 chronic schizophrenic in-patients
T3	Participants 914 1025	chronic schizophrenic patients who are intolerant of extrapyramidal side effects of conventional antipsychotics
